Prothena Corp. (PRTA) Appoints New CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Prothena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director
October 3, 2016 7:00 AM EDTDUBLIN, Ireland, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq: PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Gene Kinney, PhD has been appointed President and Chief Executive Officer of Prothena. Dr. Kinney has also been appointed to Prothenas Board of Directors. The appointments come following the passing of Prothenas Co-founder, President and CEO, Dr. Dale B. Schenk on September 30, 2016.Â
Gene is a well-known and highly respected biotechnology executive who is uniquely qualified to lead... More
